Cladribine therapy for systemic mastocytosisKLUIN-NELEMANS, Hanneke C; OLDHOFF, J. Marja; VAN DOORMAAL, Jasper J et al.Blood. 2003, Vol 102, Num 13, pp 4270-4276, issn 0006-4971, 7 p.Article

Efficient syntheses of 2-chloro-2'-deoxyadenosine (cladribine) from 2'-deoxyguanosineJANEBA, Zlatko; FRANCOM, Paula; ROBINS, Morris J et al.Journal of organic chemistry. 2003, Vol 68, Num 3, pp 989-992, issn 0022-3263, 4 p.Article

Successful treatment of cutaneous langerhans cell histiocytosis with thalidomideSANDER, C. S; KAATZ, M; ELSNER, P et al.Dermatology (Basel). 2004, Vol 208, Num 2, pp 149-152, issn 1018-8665, 4 p.Article

Seventy-nine-year-old man with Langerhans cell histiocytosis treated with cladribineBLACK, Allyson; BERSHOW, Andrea; ALLEN, Pamela S et al.Journal of the American Academy of Dermatology. 2011, Vol 65, Num 3, pp 681-683, issn 0190-9622, 3 p.Article

Perspectives on purine analoguesCHESON, B. D.Hematology and cell therapy (Print). 1996, Vol 38, pp S109-S116, issn 1269-3286, SUP2Article

The clinical pharmacokinetics of cladribineLILIEMARK, J.Clinical pharmacokinetics. 1997, Vol 32, Num 2, pp 120-131, issn 0312-5963Article

Mastocytosis: update on pharmacotherapy and future directionsCARLOS CARDET, Juan; AKIN, Cem; MIN JUNG LEE et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 15, pp 2033-2045, issn 1465-6566, 13 p.Article

Significant efficacy of 2-chlorodeoxyadenosine± rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-upCERVETTI, G; GALIMBERTI, S; PELOSINI, M et al.Annals of oncology. 2013, Vol 24, Num 9, pp 2434-2438, issn 0923-7534, 5 p.Article

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) studyCOOK, S; VERMERSCH, P; VIGLIETTA, V et al.Multiple sclerosis. 2011, Vol 17, Num 5, pp 578-593, issn 1352-4585, 16 p.Article

Novel Therapeutic Approaches to Autoimmune Demyelinating DisordersSANVITO, Lara; CONSTANTINESCU, Cris S; GRAN, Bruno et al.Current pharmaceutical design (Print). 2011, Vol 17, Num 29, pp 3191-3201, issn 1381-6128, 11 p.Article

Hairy Cell Leukemia: Evaluation of the Long-Term Outcome in 121 PatientsLUIGI ZINZANI, Pier; PELLEGRINI, Cinzia; STEFONI, Vittorio et al.Cancer. 2010, Vol 116, Num 20, pp 4788-4792, issn 0008-543X, 5 p.Article

Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in JapanIMAMURA, Toshihiko; SATO, Takashi; SHIOTA, Yoko et al.International journal of hematology. 2010, Vol 91, Num 4, pp 646-651, issn 0925-5710, 6 p.Article

Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylationCHTIOUI, Haithem; MILLIUS, Claudine; LÄMMLE, Bernhard et al.British journal of haematology. 2009, Vol 144, Num 1, pp 136-137, issn 0007-1048, 2 p.Article

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosisELSE, Monica; DEARDEN, Claire E; LAURIA, Francesco et al.British journal of haematology. 2009, Vol 145, Num 6, pp 733-740, issn 0007-1048, 8 p.Article

Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cellsBAYA BOUZAR, Amel; BOXUS, Mathieu; CHATELAIN, Bernard et al.British journal of haematology. 2009, Vol 144, Num 1, pp 41-52, issn 0007-1048, 12 p.Article

Oligoarthrite à histiocytes spumeux associée à une histiocytose systémique langerhansienne: observation et revue de la littératureAOUBA, Achille; LAROUSSERIE, Frédérique; LE GUERN, Véronique et al.Revue du rhumatisme (Ed. française). 2009, Vol 76, Num 12, pp 1351-1355, issn 1169-8330, 5 p.Article

Disease-Modifying Agents for Multiple Sclerosis : Recent Advances and Future ProspectsMENGE, Til; WEBER, Martin S; STÜVE, Olaf et al.Drugs (Basel). 2008, Vol 68, Num 17, pp 2445-2468, issn 0012-6667, 24 p.Article

In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantroneKOBYLINSKA, Agnieszka; BEDNAREK, Jolanta; BLONSKI, Jerzy Z et al.Oncology reports. 2006, Vol 16, Num 6, pp 1389-1395, issn 1021-335X, 7 p.Article

Mastocytoses: avancées dans le diagnostic moléculaire et la thérapeutique = Mastocytosis: advances in molecular diagnosis and therapeuticsAROCK, M.Annales pharmaceutiques françaises. 2004, Vol 62, Num 4, pp 233-243, issn 0003-4509, 11 p.Article

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211BYRD, I. C; PETERSON, B; PIRO, L et al.Leukemia. 2003, Vol 17, Num 2, pp 323-327, issn 0887-6924, 5 p.Article

Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistanceMANSSON, Emma; FLORDAL, Emma; LILIEMARK, Jan et al.Biochemical pharmacology. 2003, Vol 65, Num 2, pp 237-247, issn 0006-2952, 11 p.Article

Extended follow-up of patients with hairy cell leukemia after treatment with cladribineGOODMAN, Grant R; BURIAN, Carol; KOZIOL, James A et al.Journal of clinical oncology. 2003, Vol 21, Num 5, pp 891-896, issn 0732-183X, 6 p.Article

Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulinNAKAI, K; KANDA, Y; MAKIMOTO, A et al.Bone marrow transplantation (Basingstoke). 2002, Vol 29, Num 3, pp 237-241, issn 0268-3369Article

Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failureCREWS, Kristine R; WIMMER, Peggy S; HUDSON, Joanna Q et al.Journal of pediatric hematology/oncology. 2002, Vol 24, Num 8, pp 677-680, issn 1077-4114, 4 p.Article

Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignanciesROBAK, Tadeusz; GORA-TYBOR, Joanna; LECH-MARANDA, Ewa et al.European journal of haematology. 2001, Vol 66, Num 3, pp 188-194, issn 0902-4441Article